Phase 1CompletedINTERVENTIONAL
Multiple Ascending Dose Study of AMG 598 in Adults With Obesity
ClinicalTrials.gov · NCT03757130 · Registry updated: 2023-09-14
- Condition / research focus
- Obesity
- Sponsor
- Amgen
- Countries with listed sites
- United States
- Registry dates and results
- Start: 2018-11-26. Completion: 2019-12-16 (may be estimated). Results are posted in this registry.
Products and interventions (3)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- AMG 598 (drug)
- Placebo (drug)
- Liraglutide (drug) — also listed as: Saxenda®
Where the study takes place — 4 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- William D Summers MD LLC
Birmingham, Alabama, United States
Site recruitment: Not reported - Tustin, California, United States